Kairos Pharma (KAPA) Stock Price, News & Analysis

Company Overview

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics. The company collaborates with academic institutions and patient advocacy groups to advance its programs through clinical milestones and facilitate patient access. By concentrating on precision modulation of the translational machinery, Kairos Pharma aims to address diseases with high unmet medical need and no currently approved treatments.

Governed by an experienced leadership team with backgrounds in drug development, regulatory affairs and commercial strategy, Kairos Pharma maintains research operations in the United States and Europe. The company continues to forge strategic partnerships and secure financing to support its development programs and expand its pipeline. With a science‐driven approach and commitment to rare disease communities, Kairos Pharma is positioned to deliver innovative therapies to patients worldwide.

Key Stats

• Today's Range: $1.83 to $2.10
• 50-Day Range: $0.65 to $1.97
• 52-Week Range: $0.40 to $4.00
• Volume: 1.09 million shs
• Average Volume: 1.55 million shs
• Market Capitalization: $38.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.33
• Consensus Rating: Buy

Kairos Pharma Stock Analysis - MarketRank™

Kairos Pharma scored higher than 26% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Kairos Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Kairos Pharma has a consensus price target of $8.33, representing about 350.5% upside from its current price of $1.85.

Amount of Analyst Coverage

Kairos Pharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Kairos Pharma is -5.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kairos Pharma is -5.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Kairos Pharma has a P/B Ratio of 5.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for KAPA.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kairos Pharma does not currently pay a dividend.

Dividend Growth

Kairos Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for KAPA.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 12 people have searched for KAPA on MarketBeat in the last 30 days. This is a decrease of -8% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Kairos Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

39.60% of the stock of Kairos Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

KAPA Stock Analysis - Frequently Asked Questions

How have KAPA shares performed this year?

Kairos Pharma's stock was trading at $1.53 at the beginning of the year. Since then, KAPA stock has increased by 20.9% and is now trading at $1.85.

Who are Kairos Pharma's major shareholders?

Kairos Pharma's top institutional shareholders include XTX Topco Ltd (0.31%).

How do I buy shares of Kairos Pharma?

Shares of KAPA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 9/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEAMERICAN:KAPA
• CIK: 1962011
• Web: N/A
• Phone: (818) 404-5541
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Kairos Pharma: $8.33
• High Price Target: $12.00
• Low Price Target: $4.00
• Potential Upside/Downside: +350.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$2.60 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -88.73%
• Return on Assets: -74.24%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.16
• Quick Ratio: 7.16

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.35 per share
• Price / Book: 5.29

Miscellaneous

• Outstanding Shares: 20,740,000
• Free Float: 13,836,000
• Market Cap: $38.37 million
• Optionable: N/A
• Beta: N/A